Curis (NASDAQ:CRIS) Rating Reiterated by HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $26.00 target price on the biotechnology company’s stock. HC Wainwright’s target price would suggest a potential upside of 383.27% from the stock’s current price.

Curis Trading Up 6.1 %

Shares of NASDAQ:CRIS opened at $5.38 on Friday. Curis has a twelve month low of $3.80 and a twelve month high of $17.49. The company’s 50 day moving average is $5.34 and its 200 day moving average is $9.14. The company has a market cap of $31.71 million, a PE ratio of -0.62 and a beta of 3.33.

Curis (NASDAQ:CRIS) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($2.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.36). The business had revenue of $2.55 million during the quarter, compared to analyst estimates of $2.20 million. Curis had a negative return on equity of 327.92% and a negative net margin of 468.18%. During the same quarter in the previous year, the company earned ($2.40) EPS. Equities research analysts predict that Curis will post -6.79 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Curis

Several institutional investors and hedge funds have recently modified their holdings of CRIS. Franklin Street Advisors Inc. NC acquired a new stake in Curis during the first quarter worth about $219,000. Focused Wealth Management Inc boosted its position in Curis by 79.2% in the 1st quarter. Focused Wealth Management Inc now owns 33,158 shares of the biotechnology company’s stock worth $360,000 after purchasing an additional 14,656 shares in the last quarter. Point72 Asset Management L.P. grew its stake in shares of Curis by 795.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock worth $748,000 after purchasing an additional 96,256 shares during the period. CM Management LLC increased its holdings in shares of Curis by 380.0% during the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after purchasing an additional 95,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in shares of Curis by 4.8% in the 1st quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock valued at $2,376,000 after purchasing an additional 10,097 shares during the period. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.